To provide a compound and a tumor therapeutic agent which are highly effective in cancer therapy and are less likely to cause hypertension as a side effect, and to provide development of a drug for elucidating the action mechanism of lenvatinib to help further development of new drugs.The lenvatinib derivative of the present invention comprises a compound represented by the following chemical structural formula (1) (wherein R represents an alkylene group which may have a branch) and a salt thereof, and a solvate thereof. This derivative has a nitric acid ester group, and thus produces nitric oxide (NO) having a vasodilating action in vivo, so that a higher-concentration lenvatinib component can be expected to arrive at target molecules present in cancer cells and vascular endothelial cells on the host side and also can suppress hypertension as a side effect.